by The diagnostic radiopharmaceuticals and contrast media market has been growing rapidly owing to the increasing use of medical imaging modalities like CT scans, MRIs, ultrasounds for diagnosing various diseases. Diagnostic radiopharmaceuticals and contrast media are used to enhance the visibility of internal structures and blood flow in the organs and tissues on medical images. The diagnostic radiopharmaceuticals act as tracers by emitting radiation that can be detected by special cameras, while contrast media help in enhancing the contrast between tissues on medical images. The global diagnostic radiopharmaceuticals and contrast media market is estimated to be valued at US$ 7846.74 Bn in 2024 and is expected to exhibit a CAGR of 7.4% over the forecast period 2024 to 2030.
Diagnostic radiopharmaceuticals and contrast media find wide application in disease diagnostics, cancer detection, neurology, cardiology and other areas. The continuous technological advancements in medical imaging equipment like high field MRI systems and multislice CT scanners have resulted in an increased demand for diagnostic radiopharmaceuticals and contrast media to obtain high resolution images. These agents play a crucial role in non-invasive diagnosis of diseases by aiding physicians to detect abnormalities. The growing geriatric population suffering from target diseases and increasing awareness about the benefits of early disease diagnosis are some of the key factors accelerating the demand for diagnostic radiopharmaceuticals and contrast media.
Key Takeaways
Key players operating in the diagnostic radiopharmaceuticals and contrast media market are BASF SE, Akzo Nobel N.V., Arkema Group, PPG Industries Inc., Axalta Coating System LLC., The Valspar Corporation, The Sherwin-Williams Company, Croda International Plc., Watson Coatings, Inc., Allnex Belgium SA/NV, Sokan New Materials, and Dymax Corporation.
The key opportunities in the market include increasing healthcare expenditures in emerging nations, growing demand for personalised medicine approaches, and development of novel diagnostic radiotracers and contrast agents.
Some of the technological advancements in the market include development of artificial intelligence integrated medical imaging systems, nanoparticle based contrast agents, and molecularly targeted radiopharmaceuticals.
Market Drivers
Increasing incidence of target diseases like cancer, cardiovascular diseases, neurological disorders is a major factor augmenting the demand for diagnostic radiopharmaceuticals and contrast media. As per statistical estimates, cancer incidence is expected to increase by over 70% in the next 20 years. This prevalent disease condition will propel the need for accurate diagnostic tests relying on radiopharmaceuticals and contrast agents.
The rising investments by governments and private players in the medical imaging sector for facilitating early disease diagnosis is expected to fuel the diagnostic radiopharmaceuticals and contrast media market growth over the coming years. The implementation of favorable regulatory guidelines to promote the development and adoption of advanced diagnostic techniques will further push the market on an upward trajectory.
The Diagnostic Radiopharmaceuticals And Contrast Media Market Demand is facing challenges due to the stringent regulations and guidelines imposed by regulatory bodies for approval of new products. Long approval timelines and high costs associated with clinical trials and regulatory requirements add to the challenges. Substitutes available for some contrast agents also pose a challenge. Reliance on reimbursements from medical insurance and public healthcare systems affects the market. The covid-19 pandemic disrupted supply chains and production temporarily.
SWOT Analysis
Strength: Advanced technologies for improved imaging capabilities. Wide applications in diagnostic procedures.
Weakness: Stringent regulatory norms. Risks of side effects or allergic reactions.
Opportunity: Growing elderly population. Rising incidence of chronic diseases. Emerging economies providing scope for market growth.
Threats: Shift towards safer alternatives. Price control measures in some regions. Vulnerability to economic downturns affecting healthcare budgets.
Geographically, the diagnostic radiopharmaceuticals and contrast media market in North America dominates in terms of value share currently. This is attributed to the large healthcare expenditure, technologically advanced healthcare infrastructure and favorable reimbursement policies in the region. Europe is another major market aided by public healthcare support. Asia Pacific is poised to be the fastest growing regional market over the forecast period owing to rising medical tourism, growing healthcare expenditures and increasing chronic disease prevalence in developing nations.
The diagnostic radiopharmaceuticals and contrast media market in China, followed by India, is anticipated to experience high growth rates during the forecast period. Factors such as the presence of a large patient pool, increasing investments in healthcare sectors by governments, and expanding medical insurance coverage are contributing to the rapid market growth. Rising affordability of healthcare services in middle-income patients aids market prospects.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
